{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:45:56Z","timestamp":1787240756360,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.02.014","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:34:53Z","timestamp":1771374893000},"page":"1008-1016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society"],"prefix":"10.1016","volume":"32","author":[{"given":"Vaia","family":"Lambadiari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bargiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kanaka-Gantenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Tigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zadalla","family":"Mousleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystallenia","family":"Alexandraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Daraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Kanouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Korakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.02.014_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.02.014_bib2","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib3","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/dc13-0561","article-title":"Novel forms of lipodystrophy","volume":"36","author":"Rother","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.014_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1399-0004.2002.610407.x","article-title":"Cardiomyopathy in congenital complete lipodystrophy","volume":"61","author":"Bhayana","year":"2002","journal-title":"Clin Genet"},{"key":"10.1016\/j.eprac.2026.02.014_bib5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: Comparison of baseline characteristics and response to Metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ecl.2017.01.012","article-title":"Genetics of lipodystrophy","volume":"46","author":"Lightbourne","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.eprac.2026.02.014_bib7","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a Multi-Society Practice Guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The clinical approach to the detection of lipodystrophy an aace consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.02.014_bib9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2337\/dbi24-0018","article-title":"Lipodystrophy prevalence, \u201cLipodystrophy-Like Phenotypes,\u201d and diagnostic challenges","volume":"73","author":"Akinci","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.eprac.2026.02.014_bib10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1507\/endocrj.EJ21-0110","article-title":"Practice guideline for lipodystrophy syndromes\u2014clinically important diseases of the Japan Endocrine Society (JES)","volume":"68","author":"Tanaka","year":"2021","journal-title":"Endocr J"},{"key":"10.1016\/j.eprac.2026.02.014_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","article-title":"Lipodystrophies","volume":"108","author":"Garg","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.eprac.2026.02.014_bib12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2147\/DMSO.S206053","article-title":"Familial partial lipodystrophy (FPLD): recent insights","volume":"13","author":"Bagias","year":"2020","journal-title":"DMSO"},{"key":"10.1016\/j.eprac.2026.02.014_bib13","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and Leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molimm.2019.05.011","article-title":"An overview of lipodystrophy and the role of the complement system","volume":"112","author":"Corvillo","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.eprac.2026.02.014_bib15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2337\/dc18-0978","article-title":"\u201cFat Shadows\u201d from DXA for the qualitative assessment of lipodystrophy: when a picture is worth a thousand numbers","volume":"41","author":"Meral","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.014_bib16","first-page":"907","article-title":"Lipodystrophy: a paradigm for understanding the consequences of \u2018overloading\u2019 adipose tissue","volume":"101","author":"Lim","year":"2020","journal-title":"Physiol Rev"},{"key":"10.1016\/j.eprac.2026.02.014_bib17","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.3748\/wjg.v29.i17.2534","article-title":"Non-invasive evaluation of liver steatosis with imaging modalities: new techniques and applications","volume":"29","author":"Zeng","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.eprac.2026.02.014_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and management of Non-HIV\u2013Related lipodystrophy in children: a systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib19","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0026-0495(79)90090-8","article-title":"The effect of diet on thermogenesis in acquired lipodystrophy","volume":"28","author":"Robbins","year":"1979","journal-title":"Metabolism"},{"key":"10.1016\/j.eprac.2026.02.014_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2337\/dc23-1614","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy","volume":"47","author":"Foss-Freitas","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.014_bib21","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/dom.16175","article-title":"Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: real-life experience from a national reference network","volume":"27","author":"Lamothe","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib22","first-page":"e71","article-title":"Oral glucagon-like peptide 1 analog as an adjuvant therapy in generalized lipodystrophy","volume":"48","author":"Lebenthal","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.014_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study","volume":"16","author":"Oral","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.eprac.2026.02.014_bib24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.eprac.2026.02.014_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4158\/EP09155.RA","article-title":"Rationale for leptin-replacement therapy for severe lipodystrophy","volume":"16","author":"Oral","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.02.014_bib26","article-title":"Summary of product characteristics","year":"2024","journal-title":"EU\/EEA"},{"key":"10.1016\/j.eprac.2026.02.014_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2026.02.014_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.eprac.2026.02.014_bib29","article-title":"Familial partial lipodystrophy: clinical features, genetics and treatment in a Greek Referral Center","volume":"24","author":"Kountouri","year":"2023","journal-title":"IJMS"},{"key":"10.1016\/j.eprac.2026.02.014_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.684182","article-title":"Case report: Metreleptin treatment in a patient with a novel mutation for familial partial lipodystrophy type 3, presenting with uncontrolled diabetes and insulin resistance","volume":"12","author":"Lambadiari","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.014_bib31","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.medj.2021.04.001","article-title":"Metreleptin therapy for nonalcoholic steatohepatitis: open-label therapy interventions in two different clinical settings","volume":"2","author":"Akinci","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.eprac.2026.02.014_bib32","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.02.014_bib33","doi-asserted-by":"crossref","first-page":"e2953","DOI":"10.1210\/clinem\/dgab216","article-title":"Effect of leptin therapy on survival in generalized and partial lipodystrophy: a matched cohort analysis","volume":"106","author":"Cook","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib34","first-page":"e1051","article-title":"Effects of metreleptin in patients with generalized lipodystrophy before vs after the onset of severe metabolic disease","volume":"10","author":"Brush","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.014_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.014_bib36","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2026.02.014_bib37","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1210\/clinem\/dgaf103","article-title":"Lipodystrophy severity score to assess disease burden in lipodystrophy","volume":"110","author":"Brown","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26008013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:28:05Z","timestamp":1781018885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26008013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1530891X26008013"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.014","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}